Trial Profile
Low-dose tenecteplase versus standard-dose alteplase for acute ischaemic stroke: an Imaging-Based Efficacy Trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2021
Price :
$35
*
At a glance
- Drugs Tenecteplase (Primary) ; Alteplase
- Indications Stroke
- Focus Therapeutic Use
- Acronyms Australian-TNK
- 19 Mar 2021 Systemic review and meta-analysis this and 3 other studies (EXTEND-IA, AUSTRALIAN TNK & ATTEST), presented at the International Stroke Conference 2021.
- 13 Dec 2016 Results of pooled post-hoc analysis from TAAIS and ATTEST studies (n=146) published in the Circulation.
- 22 Mar 2012 Results published in the New England Journal of Medicine.